North Carolina nanotechnology company Liquidia Technologies is partnering with nonprofit organization PATH to develop a new pneumonia vaccine that could be deployed globally.

Research Triangle Park-based Liquidia is working with PATH to conduct preclinical studies on a “next-generation” pneumococcal vaccine that could be more effective than existing vaccines and more efficient to produce. Financial terms of the partnership were not disclosed. But it’s not the first time the two entities have worked together. Liquidia has also partnered with PATH’s Malaria Vaccine Initiative to develop a new malaria vaccine.